focus -WSS

focus

author：entertainment 2025-09-28 00:48:00 - browse：33

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： FDA early review: GLP

Wikipedia

WSS

Illumina slashes 2023 revenue projections yet again

Treatments for cramps don't cut it. Why aren't there better options?

Study suggests new cause of Down syndrome: cells linked to aging

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Does Paxlovid work in people vaccinated against Covid

Gene therapy denied for Afghan refugee whose father aided U.S.

explore

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Apple is now the first public company to be valued at $3 trillion

Surge in Apellis stock fueled by confidence in safety of its eye drug

Moonlake's readout produced a cash windfall. Risks remain

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Continuity nursing helped my family in our darkest PICU moments

Boston Scientific acquires urology company Axonics for $3.7 billion

As demand for Covid shots wanes, Moderna seeks its next success

What to know about the judge who will handle the Trump case

Jerome Adams on the need for new antivirals for Covid

Health AI: on the border between health care and tech

focus

Treatments for cramps don't cut it. Why aren't there better options?

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

Judge sides with young activists in first

Hospital chaplains balance Covid safety with patients’ spiritual needs

Bird flu researchers hone in on Finland’s mink farms

FDA early review: GLP

hotspot

knowledge

Wikipedia

hotspot